clinical trial · NCT06542536
A Research Study Investigating Safety and Concentration in the Blood After One Dose Tablet of the New Medicine Monlunabant in Healthy Weight Japanese and Caucasian Men
Novo Nordisk A/S·phase1·completed·n = 73
ObesityMonlunabantPlacebo (monlunabant)
brief summary
The study is testing a new study drug in healthy normal weight Japanese and Caucasian participants after a single dose. The aim of this study is to see if the new medicine is safe and how it works in the participants body. Oral monlunabant is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. The participant will either get monlunabant or placebo or a combination of both. Which treatment the participant get is decided by chance. The study will last for about 49 days in total.
started
Aug 9, 2024
primary completion
Oct 25, 2024
completion
Oct 25, 2024
last updated
Nov 18, 2025
official title
Investigation of Tolerability, Safety, and Pharmacokinetic Properties of a Single Oral Dose of Monlunabant in Male Japanese and Caucasian Participants With Normal Body Weight
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol